Science Board to the Food and Drug Administration; Notice of Meeting, 6332-6333 [2013-01944]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with
6332
Federal Register / Vol. 78, No. 20 / Wednesday, January 30, 2013 / Notices
(HCPPs) contracting with the Secretary
under Section 1833 of the Social
Security Act are required to submit a
budget and enrollment forecast, semiannual interim report, and final cost
report in accordance with 42 CFR
417.808 and 42 CFR 417.810. CMS is
requesting approval for the
reinstatement with change of Form
CMS–276 (OCN: 0938–0165). This Cost
Report outlines the provisions for
implementing Section 1876(h) and
Section 1833(a)(1)(A) of the Social
Security Act. The purposes of the
revisions were to implement some
changes in response to the Affordable
Care Act, clarify certain instructions,
and update outdated issues within the
Cost Report. Form Number: CMS–276
(OMB# 0938–0165); Frequency:
Annually; Affected Public: Private
Sector—Business or other for-profits
and not-for-profit institutions; Number
of Respondents: 29; Total Annual
Responses: 106; Total Annual Hours:
1,384. (For policy questions regarding
this collection contact Temeshia
Johnson at 410–786–8692. For all other
issues call 410–786–1326.)
2. Type of Information Collection
Request: Reinstatement with change of a
previously approved collection; Title of
Information Collection: Medicare
Provider Cost Report Reimbursement
Questionnaire; Use: The purpose of
Form CMS–339 is to assist the provider
in preparing an acceptable cost report
and to minimize subsequent contact
between the provider and its Medicare
Administrative Contractor (MAC). Form
CMS–339 provides the basic data
necessary to support the information in
the cost report. Exhibit 1of Form CMS–
339 contains a series of reimbursementoriented questions which serve to
update information on the operations of
the provider. It is arranged topically
regarding financial activities such as
independent audits, provider
organization and operation, etc. The
MAC is responsible for the settlement of
the Medicare cost report and must
determine the reasonableness and the
accuracy of the reimbursement claimed.
This process includes performing both a
desk review of the cost report and an
analysis leading to a decision to settle
the cost report with or without further
audit. Form CMS–339 provides essential
information to enable the MAC to make
the audit or no audit decision, scope of
the audit if one is necessary, and to
update the provider documentation (i.e.,
documentation to support the financial
profile of the provider). If the
information is not collected, the MAC
will have to go onsite to each provider
to get this information. Consequently, it
VerDate Mar<15>2010
20:43 Jan 29, 2013
Jkt 229001
is far less burdensome and extremely
cost effective to capture this information
through the Form CMS–339.
Exhibit 2 of Form CMS–339 is a
listing of bad debts pertaining to
uncollectible Medicare deductible and
coinsurance amounts. Preparation of the
listing is a convenient way for providers
to supply the MAC with information
needed to determine the allow ability of
the bad debts for reimbursement. Some
items required to determine allow
ability that are included on this exhibit
are patient’s name, dates of service, date
first bill sent to beneficiary, and date the
collection effort ceased. Supplying the
MAC with this information may be all
that is required for the MAC to
determine whether or not the bad debt
is allowable. This too may eliminate a
visit to the provider to gather this
needed data. Form Number: CMS–339
(OCN: 0938–0301); Frequency: Yearly;
Affected Public: Private Sector—
Business or other for-profits and not-forprofit institutions; Number of
Respondents: 17,939; Total Annual
Responses: 17,939; Total Annual Hours:
53,817. (For policy questions regarding
this collection contact Christine
Dobrzycki at 410–786–3389. For all
other issues call 410–786–1326.)
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web site
address at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or
Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
In commenting on the proposed
information collections please reference
the document identifier or OMB control
number. To be assured consideration,
comments and recommendations must
be submitted in one of the following
ways by April 1, 2013:
1. Electronically. You may submit
your comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) accepting comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number _________, Room C4–
26–05, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Dated: January 24, 2013.
Martique Jones,
Deputy Director, Regulations Development
Group, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2013–01849 Filed 1–29–13; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No: FDA–2013–N–0001]
Science Board to the Food and Drug
Administration; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Science Board to
the Food and Drug Administration
(Science Board).
General Function of the Committee:
The Science Board provides advice
primarily to the Commissioner of Food
and Drugs and other appropriate
officials on specific complex scientific
and technical issues important to the
FDA and its mission, including
emerging issues within the scientific
community. Additionally, the Science
Board provides advice to the Agency on
keeping pace with technical and
scientific developments including in
regulatory science; and input into the
Agency’s research agenda; and on
upgrading its scientific and research
facilities and training opportunities. It
will also provide, where requested,
expert review of Agency-sponsored
intramural and extramural scientific
research programs.
Date and Time: The meeting will be
held on Wednesday, February 27, 2013,
from approximately 8:30 a.m. to 5:15
p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(rm. 1503), Silver Spring, MD 20993.
For those unable to attend in person, the
meeting will also be webcast. The link
for the webcast is available at https://
collaboration.fda.gov/scienceboard/.
Information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
E:\FR\FM\30JAN1.SGM
30JAN1
mstockstill on DSK4VPTVN1PROD with
Federal Register / Vol. 78, No. 20 / Wednesday, January 30, 2013 / Notices
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
Contact Person: Martha Monser,
Office of the Chief Scientist, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, rm. 4286,
Silver Spring, MD 20993, 301–796–
4627, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area). A notice in the Federal Register
about last minute modifications that
impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the Agency’s Web
site at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before coming to the meeting.
Agenda: On February 27, 2013, the
Science Board will be provided with
updates and/or draft reports from the
Center for Devices and Radiological
Health Research Review subcommittee
and the Global Health subcommittee. A
progress update will be presented
regarding the recently established
Center for Biologics Evaluation and
Review Post-Marketing Safety Review
subcommittee. An update on the plan to
establish a new subcommittee to
evaluate the Agency’s continuing work
to address the challenges identified in
Science Board’s 2007 ‘‘Science and
Mission at Risk’’ Report will be
presented. Plans will also be presented
and a proposed charge reviewed for a
second subcommittee to assess similar
issues with respect to information
technology including evaluation of
scientific data utilization, data
liberation and innovation. Overviews of
genomics activities at the Centers for
Food Safety and Applied Nutrition and
Veterinary Medicine will be presented,
along with plans for an Agency-wide
working group to address cross-cutting
genomics activities. Finally, recipients
of the FY2012 Scientific Achievement
awards (selected by the Science Board)
will provide overviews of the activities
for which the awards were given.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
VerDate Mar<15>2010
20:43 Jan 29, 2013
Jkt 229001
6333
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before Wednesday,
February 20, 2013. Oral presentations
from the public will be scheduled
between approximately 4:30 p.m. and 5
p.m. Those individuals interested in
making formal oral presentations should
notify the contact person and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before Tuesday, February 12, 2013.
Time allotted for each presentation may
be limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
Wednesday, February 13, 2013.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Martha
Monser at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: January 24, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
Dated: January 24, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–01944 Filed 1–29–13; 8:45 am]
[FR Doc. 2013–01880 Filed 1–29–13; 8:45 am]
BILLING CODE 4160–01–P
BILLING CODE 4140–01–P
PO 00000
Frm 00045
Fmt 4703
Sfmt 9990
National Institutes of Health
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; VSL
Fellowships.
Date: February 21, 2013.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6120
Executive Blvd. Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Sheo Singh, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders National Institutes of Health,
Rockville, MD 20850, 301–496–8693,
singhs@nidcd.nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Training
in Hearing Research Review Meeting.
Date: February 26, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Andrea B. Kelly, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders National Institutes of Health,
Rockville, MD 20850, 301–496–8683,
kellya2@nidcd.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 78, Number 20 (Wednesday, January 30, 2013)]
[Notices]
[Pages 6332-6333]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01944]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No: FDA-2013-N-0001]
Science Board to the Food and Drug Administration; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Science Board to the Food and Drug
Administration (Science Board).
General Function of the Committee: The Science Board provides
advice primarily to the Commissioner of Food and Drugs and other
appropriate officials on specific complex scientific and technical
issues important to the FDA and its mission, including emerging issues
within the scientific community. Additionally, the Science Board
provides advice to the Agency on keeping pace with technical and
scientific developments including in regulatory science; and input into
the Agency's research agenda; and on upgrading its scientific and
research facilities and training opportunities. It will also provide,
where requested, expert review of Agency-sponsored intramural and
extramural scientific research programs.
Date and Time: The meeting will be held on Wednesday, February 27,
2013, from approximately 8:30 a.m. to 5:15 p.m.
Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building
31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD
20993. For those unable to attend in person, the meeting will also be
webcast. The link for the webcast is available at https://collaboration.fda.gov/scienceboard/. Information regarding special
accommodations due to a disability, visitor parking, and transportation
may be accessed at: https://www.fda.gov/AdvisoryCommittees/default.htm;
under the heading ``Resources for You,'' click on ``Public Meetings at
the FDA White
[[Page 6333]]
Oak Campus.'' Please note that visitors to the White Oak Campus must
enter through Building 1.
Contact Person: Martha Monser, Office of the Chief Scientist, Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 4286,
Silver Spring, MD 20993, 301-796-4627, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area). A notice in the Federal Register about last minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.
Agenda: On February 27, 2013, the Science Board will be provided
with updates and/or draft reports from the Center for Devices and
Radiological Health Research Review subcommittee and the Global Health
subcommittee. A progress update will be presented regarding the
recently established Center for Biologics Evaluation and Review Post-
Marketing Safety Review subcommittee. An update on the plan to
establish a new subcommittee to evaluate the Agency's continuing work
to address the challenges identified in Science Board's 2007 ``Science
and Mission at Risk'' Report will be presented. Plans will also be
presented and a proposed charge reviewed for a second subcommittee to
assess similar issues with respect to information technology including
evaluation of scientific data utilization, data liberation and
innovation. Overviews of genomics activities at the Centers for Food
Safety and Applied Nutrition and Veterinary Medicine will be presented,
along with plans for an Agency-wide working group to address cross-
cutting genomics activities. Finally, recipients of the FY2012
Scientific Achievement awards (selected by the Science Board) will
provide overviews of the activities for which the awards were given.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
Wednesday, February 20, 2013. Oral presentations from the public will
be scheduled between approximately 4:30 p.m. and 5 p.m. Those
individuals interested in making formal oral presentations should
notify the contact person and submit a brief statement of the general
nature of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
Tuesday, February 12, 2013. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person will
notify interested persons regarding their request to speak by
Wednesday, February 13, 2013.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Martha Monser at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: January 24, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2013-01944 Filed 1-29-13; 8:45 am]
BILLING CODE 4160-01-P
